Skip to main content

Introducing G4

An innovative benchtop sequencing platform with novel, high-performance chemistry and advanced engineering, optimized to deliver unmatched power, speed, and versatility.

Designed for Superior Performance

15–400 Gb
Output

Delivers more data per day than any benchtop sequencer.

6–19 Hour
Run Times

Raising the bar with industry-leading run times.

4 Flow Cells
16 Lanes

Intentionally designed to maximize operational efficiency.

The World’s Most Powerful Benchtop Sequencer

The G4 is an innovative sequencing platform with novel high-performance chemistry and advanced engineering, optimized to deliver unmatched power, speed, and versatility.

Watch G4 Video

Play Video about The World’s Most Powerful Benchtop Sequencer

A Singular Focus

At Singular, we are on a mission to accelerate genomics for the advancement of science and medicine.

We are forward-thinking and driven by impactful innovation. About Us
We are purposeful and collaborative in our approach. We are advancing genomics, together. Join Us

Larry Fong

Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has also been involved in multiple first-in-human clinical trials including trials of dendritic cell vaccines, ipilimumab and an adenosine receptor antagonist. Dr. Fong’s research examines the mechanisms that underlie clinical response and resistance to immunotherapies. This work includes tracking antigen-specific T cell responses in treated cancer patients and developing biomarkers that are associated with clinical outcomes. The Cancer Immunotherapy Program that he directs performs early phase and high risk clinical trials across different disease indications. This program also includes a translational laboratory that performs mechanistic studies on samples derived from patients undergoing treatment. Throughout his career, Dr. Fong has received multiple awards including the NIH Outstanding Investigator Award.

Dr. Fong obtained his BA from Columbia and MD from Stanford. He completed internal medicine training at University of Washington, and oncology fellowship and post-doctoral training at Stanford in 2002. He then moved to UCSF as an assistant professor where he is now a distinguished professor. He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation. He has over 100 publications in journals including NEJM, Nature, Nature Medicine, Cell, Immunity, and Cancer Discovery. He has served on multiple NIH study sections, the NCI Steering Committees for Genitourinary Cancer (GUSC), the NCI Investigational Drugs (IDSC)-Immunotherapy Task Force, the Department of Defense Prostate Cancer Research Program (PCRP) Vision Setting Committee, and NCI Immuno-oncology Translation Network (IOTN) Steering Committee. He has also served on multiple journal editorial boards including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research.

Dr. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. He has ongoing research collaborations with Abbvie, Amgen, Bavarian Nordic, Bristol Myer Squibb, Dendreon, Janssen, Merck, and Roche/Genentech. He sits on the steering committee of the Roche/Genentech imCORE network. He also has served on multiple scientific advisory boards including Alector (ALEC), Atreca (BCEL), Bioatla (BCAB), Bolt (BOLT), Ideaya (IDYA), Innovent (IVBXF) Nutcracker, RAPT (RAPT), Senti, Soteria, TeneoBio (acquired by Amgen), and Xyphos (acquired by Astellas).